| Drug ID: | Drug193 |
|---|---|
| Drug Name: | Olsalazine |
| CID: | 22419 |
| DrugBank ID: | DB01250 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00004288 |
| Molecular Formula: | C14H10N2O6 |
| Molecular Weight: | 302.24 g/mol |
| Isomeric SMILES: | C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O |
| Synonyms: | Olsalazine; 15722-48-2; Olsalazina; Olsalazinum; 5,5'-Azobis(salicylic acid); C. i. mordant yellow 5; 5,5'-azodisalicylic acid; ULS5I8J03O; Benzoic acid, 3,3'-azobis(6-hydroxy-; Azodisal |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 1 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1353 | 22419 | Olsalazine | 5742 | PTGS1 | Homo sapiens (human) | 12950415 | Inhibitor |
| dt1354 | 22419 | Olsalazine | 5743 | PTGS2 | Homo sapiens (human) | 12950415 | Inhibitor |
| dt1355 | 22419 | Olsalazine | 7172 | TPMT | Homo sapiens (human) | Inhibitor | |
| dt1356 | 22419 | Olsalazine | 7498 | XDH | Homo sapiens (human) | 3067340 | Inhibitor |
| dt1357 | 22419 | Olsalazine | 56606 | SLC2A9 | Homo sapiens (human) | 32863294 | Downregulator |
| dt1358 | 22419 | Olsalazine | 9356 | SLC22A6 | Homo sapiens (human) | 32863294 | Upregulator |
| dt1359 | 22419 | Olsalazine | 9376 | SLC22A8 | Homo sapiens (human) | 32863294 | Upregulator |
| dt1360 | 22419 | Olsalazine | 6574 | SLC20A1 | Homo sapiens (human) | 32863294 | Upregulator |
| dt1361 | 22419 | Olsalazine | 476 | ATP1A1 | Homo sapiens (human) | Inhibitor | |
| dt1362 | 22419 | Olsalazine | 477 | ATP1A2 | Homo sapiens (human) | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT04985968 | The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | PHASE3 | TERMINATED | InDex Pharmaceuticals | Ulcerative Colitis | DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… | Details |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants | PHASE1 | RECRUITING | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK4528287|DRUG: Placebo | Details |
| NCT05992142 | ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA | PHASE4 | COMPLETED | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Ulcerative Colitis | DRUG: 5-ASA | Details |
| NCT00787202 | A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: CP- 690 550|DRUG: CP- 690 550|DRUG: CP- 690… | Details |
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT00207688 | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients | None | COMPLETED | Janssen Research & Development, LLC | Ulcerative Colitis | DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… | Details |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2 | TERMINATED | Nektar Therapeutics | Colitis, Ulcerative | DRUG: LY3471851|DRUG: Placebo | Details |
| NCT02958865 | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… | Details |
| NCT03943550 | Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) | PHASE1 | TERMINATED | Hoffmann-La Roche | Ulcerative Colitis | DRUG: RO7049665|DRUG: Placebo | Details |
| NCT02840721 | Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Telavant, Inc. | Colitis, Ulcerative | DRUG: PF-06480605 | Details |
| NCT04133194 | Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis | PHASE4 | RECRUITING | Flemming Bendtsen | Ulcerative Colitis | DRUG: Mesalazine|DRUG: Mesalazine | Details |
| NCT01465763 | A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT06636656 | A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis | PHASE2 | RECRUITING | Boehringer Ingelheim | Ulcerative Colitis | DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… | Details |
| NCT04996797 | A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) | PHASE2 | ACTIVE_NOT_RECRUITING | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Ulcerative Colitis | DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… | Details |
| NCT01458951 | A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT04499495 | Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea | None | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | OTHER: PENTASA (mesalamine/ 5-Aminosalicylic acid… | Details |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | PHASE2 | COMPLETED | Janssen Research & Development, LLC | Colitis, Ulcerative | DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… | Details |
| NCT02318667 | Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). | PHASE4 | COMPLETED | Merck Sharp & Dohme LLC | Colitis, Ulcerative | BIOLOGICAL: Golimumab | Details |
| NCT00317356 | A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis | PHASE2 | TERMINATED | Otsuka Pharmaceutical Co., Ltd. | Colitis, Ulcerative | DRUG: OPC-6535(Tetomilast) | Details |
| NCT01470612 | Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: CP-690,550|DRUG: CP-690,550 | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
An Olsalazine-Loaded Hollow Mesoporous Prussian Blue/Polydopamine Nanozyme Alle…
PMID: 40699132
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Individuals diagnosed with inflammatory bowel disease (IBD) exhibit a markedly elevated prevalence of psychiatric disorders, particularly anxiety and…
Oral olsalazine/ellagic acid/ZnCl(2)-modified in situ-forming hydrogels allevia…
PMID: 40688678
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a kind of chronic non-specific intestinal inflammatory disease, which accompanied by various abnormal psychologic…
An olsalazine nanoneedle-embedded inulin hydrogel reshapes intestinal homeostas…
PMID: 38024237
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic and refractory condition characterized by disrupted epithelial barrier, dysregulated immune balance, an…
The effect of olsalazine of chinese generic drugs on ulcerative colitis induced…
PMID: 37610966
Year: 2023
Relationship Type:
Treatment
Score: 6.5
PURPOSE: To explore effect and mechanism of olsalazine of Chinese generic drugs on ulcerative colitis induced by dextran sulfate sodium salt (DSS) in…
Orally Administrated Olsalazine-Loaded Multilayer Pectin/Chitosan/Alginate Comp…
PMID: 37068182
Year: 2023
Relationship Type:
Treatment
Score: 6.5
The pathogenesis of inflammatory bowel diseases (IBDs) including ulcerative colitis (UC) and Crohn's disease is extremely cloudy. Maintaining the lev…
Copper-olsalazine metal-organic frameworks as a nanocatalyst and epigenetic mod…
PMID: 36087871
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Despite the extensive explorations of nanoscale metal-organic frameworks (nanoMOFs) in drug delivery, the intrinsic bioactivity of nanoMOFs, such as …
Pharmacokinetic and gut microbiota analyses revealed the effect of Lactobacillu…
PMID: 35697287
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Olsalazine is a typical 5-aminosalicylic acid (5-ASA) drug that depends on gut microbiota to liberate its anti-inflammatory moiety 5-ASA in the treat…
Technetium-99 m labeling and evaluation of olsalazine: a novel agent for ulcera…
PMID: 26031480
Year: 2015
Relationship Type:
Association
Score: 6.3
Ulcerative colitis is a chronic disease having a regressive nature. Commonly used diagnostic methods have the disadvantage to be invasive, time-consu…